SciTransfer
TUBE · Project

How Traffic Nanoparticles Damage Your Brain — And What Industry Must Do Next

healthPrototypeTRL 3Thin data (2/5)
tube-project.eu

You know how car exhaust makes the air smell bad? It turns out the tiniest particles in that exhaust — so small they're invisible even under a regular microscope — can actually travel from your lungs into your brain. This project gathered 17 research teams across 11 countries to figure out exactly how these particles cause damage, including links to Alzheimer's disease. They built new lab models of brain tissue, exposed them to real traffic pollution, and showed that current regulations only measure particles above 23 nanometers — missing the smallest and potentially most dangerous ones entirely.

By the numbers
17
research partners in the consortium
11
countries involved
23nm
current regulatory particle size threshold challenged by this research
21
deliverables produced
4
industry partners including SMEs
EUR 5,049,876
EU research investment
The business problem

What needed solving

Current EU emission regulations only measure particles above 23nm, leaving the smallest and most health-damaging traffic nanoparticles completely unmonitored. Growing evidence links these ultrafine particles to Alzheimer's disease and other brain conditions, creating a looming regulatory and liability risk for automotive manufacturers, air quality companies, and urban health providers. Companies lack the toxicological data and testing tools needed to assess their exposure to this risk.

The solution

What was built

The project developed a new cell model (D23) for testing ultrafine particle toxicity on brain neurovascular tissue, and produced 21 deliverables covering mechanisms that link traffic nanoparticles to neurological damage. The research combined cell culture testing, animal exposure studies, human volunteer studies, and epidemiological cohort analysis to build a comprehensive evidence base.

Audience

Who needs this

Automotive engine and exhaust filtration manufacturers facing tighter emission standardsAir quality monitoring sensor companies needing to detect sub-23nm particlesOccupational health consultants serving clients near high-traffic zonesUrban planning and smart city firms designing low-pollution zonesPharmaceutical and biotech companies researching pollution-linked Alzheimer's disease
Business applications

Who can put this to work

Automotive & Engine Manufacturing
enterprise
Target: Engine and exhaust system manufacturers

If you are an engine manufacturer preparing for tighter emission standards — this project produced toxicological evidence showing that ultrafine particles below 23nm, currently unmeasured by regulations, cause brain inflammation and neurotoxicity. With 17 partners across 11 countries validating these findings, upcoming EU regulation changes will likely target these sub-23nm particles. Companies that redesign filtration systems now will be ahead of compliance deadlines.

Air Quality Monitoring & Sensors
SME
Target: Environmental monitoring equipment companies

If you are an air quality sensor company whose devices measure particles only down to the current regulatory threshold — this project demonstrated that the most health-damaging particles are below 23nm and go undetected by standard equipment. The consortium's aerosol technology experts developed new measurement approaches across 21 deliverables. Sensor companies that expand detection ranges now will capture a growing market as cities demand better monitoring.

Occupational Health & Safety
any
Target: Workplace health consultants and equipment suppliers

If you are an occupational health provider serving clients near high-traffic zones — this project linked traffic ultrafine particles to Alzheimer's disease risk, inflammation, and genotoxic damage in workers chronically exposed to traffic exhaust. The research used human exposure studies alongside cell and animal models. Updating your risk assessments and protective equipment recommendations with this evidence strengthens your service offering.

Frequently asked

Quick answers

What would it cost to access TUBE's research data or testing methods?

TUBE was a publicly funded RIA project with EUR 5,049,876 in EU contribution. As a Research and Innovation Action, most scientific outputs are published under open access. Licensing specific cell models like the D23 neurovascular unit model would require negotiation with the coordinating university in Finland.

Can the testing methods be scaled for industrial use?

The project developed new cell models (including D23) for screening ultrafine particle toxicity on brain tissue. These are laboratory-scale tools designed for research and regulatory testing, not mass production. Scaling would require partnering with the 4 industry partners already in the consortium who have experience translating these methods.

What about intellectual property and licensing?

The project coordinator is the University of Eastern Finland (ITA-SUOMEN YLIOPISTO). IP rights for novel cell models and testing protocols would be held by consortium members under standard Horizon 2020 grant agreement terms. Licensing discussions should start with the coordinator.

How does this affect current and upcoming regulations?

The project directly challenges current EU emission regulations, which only measure particles above 23nm. TUBE produced evidence that sub-23nm particles cause neurological damage, meaning new regulatory thresholds are likely. Companies in automotive, air quality, and urban health sectors should prepare for stricter particle measurement requirements.

When could this research impact my business?

The project ran from 2019 to 2023 and is now closed, with 21 deliverables completed. Regulatory changes informed by this type of research typically take 3-5 years to implement. However, companies that act now on the evidence will avoid costly last-minute compliance scrambles.

How reliable are these findings?

The consortium of 17 partners across 11 countries used multiple validation approaches: cell cultures, animal exposures, human volunteer studies, and epidemiological cohort data. This multi-method approach across 8 universities and 4 research organizations provides strong cross-validation of findings.

Can these testing tools integrate with our existing product development?

The D23 cell model and other toxicological tools can be integrated into product testing pipelines for engine manufacturers, filter producers, and air quality device makers. Based on available project data, the 4 SMEs in the consortium could potentially serve as integration partners with practical industry experience.

Consortium

Who built it

The TUBE consortium is research-heavy but credible for its purpose: 8 universities and 4 research organizations provide deep scientific authority across aerosol technology, neurotoxicology, and epidemiology. The 4 industry partners (24% of the consortium) and 4 SMEs signal real-world relevance, though the primary output is evidence rather than products. Spanning 11 countries — including non-EU participants from China, Chile, and the UK — gives the findings global applicability. For a business looking to partner, the Finnish coordinator (University of Eastern Finland) is the entry point, but the industry partners would be the most practical collaborators for translating research into commercial testing services or product improvements.

How to reach the team

University of Eastern Finland (ITA-SUOMEN YLIOPISTO) — contact via project website or university research office

Order a report on this consortiumSee ITA-SUOMEN YLIOPISTO profile →
Next steps

Talk to the team behind this work.

Want to know which TUBE partners could help your company prepare for sub-23nm particle regulations? SciTransfer can connect you with the right consortium member for your specific need.

Order a report on this topicMore in Health & Biomedical
More in Health & Biomedical
See all Health & Biomedical projects →
Automated Allergy Test Covering All Allergens in One Run, Ready to Ship
AllergyExplorer
Open →
Lab-Sized 3D Cell Microscope Replaces 12-Month Waits at Giant Synchrotron Facilities
LICENT
Open →
Blood Test Platform That Catches Rare Diseases Early Using AI-Powered Diagnostics
METAdiag
Open →